RecruitingPhase 4

Comparing Antipsychotic Medications in LBD Over Time

United States94 participantsStarted 2022-04-22

Plain-language summary

The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to as Lewy body disease (LBD).

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients seen in the neurology clinic at UT Health San Antonio * Diagnosed with psychosis due to PD or DLB * Requiring initiation of an antipsychotic medication * Clinical equipoise between quetiapine and pimavanserin must exist * The prescribing provider must be comfortable prescribing and managing both quetiapine and pimavanserin Exclusion Criteria: * Medical contraindication to either medication * Caregiver unavailable to complete NPI-Q * Currently taking an antipsychotic medication * Prescribing provider unwilling to manage either medication

What they're measuring

Neuropsychiatry Inventory Questionnaire (NPI-Q), Hallucinations + Delusions (H+D)

Timeframe: Baseline to 6 months

Trial details

NCT IDNCT05590637

SponsorThe University of Texas Health Science Center at San Antonio

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-08

Contact for this trial

Carolyn Paiz, BS

210-450-8830 paizc@uthscsa.edu

View on ClinicalTrials.gov More Parkinson's Disease Psychosis trials